Has Matthew Austin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $986,213 in general payments to Matthew Austin, MD across 278 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Austin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Austin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Austin, MD

Adult Reconstructive Orthopaedic Surgery · New York, NYNPI 1518914886

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $705,135 of the $986,213 with a category attached, or 71.5%. 9 manufacturers reported payments, led by Zimmer Biomet at 41.5% of the total. Among adult reconstructive orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$986,213in general payments, 2019–2025

Across 278 payments — averaging $3547.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Zimmer Biomet$409K
Stryker$372K
Depuy Synthes Products, Inc.$71K
Corin USA$56K
Medical Device Business Services, Inc.$38K
Omnilife Science, Inc$22K
plus $19K from 3 others

$53,236in research payments, 2019–2025

Across 14 payments — averaging $3802.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Omnilife Science, Inc$40K
Zimmer Biomet$13K

$200,662in ownership & investment interests, 2019–2025

Across 6 payments — averaging $33,444 each. An ownership or investment interest held by the physician or an immediate family member.

Omnilife Science, Inc$201K

What the payments were for

Royalty or licence$705,13571%
Consulting fees$242,86925%
Travel & lodging$32,1013%
Food & beverage$5,6051%
Education$5040%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Zimmer Biomet	14	$409,074
Stryker	138	$371,799
Depuy Synthes Products, Inc.	45	$70,830
Corin USA	24	$55,758
Medical Device Business Services, Inc.	21	$38,375
Omnilife Science, Inc	17	$21,693
Linkbio Corp	11	$18,118
Smith+Nephew	6	$555
Heraeus Medical, LLC.	2	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Persona$408,501
INSIGNIA$272,001
Kincise$46,506
MAKO$41,126
Velys$21,815
ACTIS$19,650
OMNIBotics 3.0$11,700
TRIATHLON$7,500
CORAIL$6,435
PINNACLE$6,435
VELYS Hip Navigation$4,095
ATTUNE$3,904
EXETER$2,500
TRITANIUM$2,500
Kincise Surgical Automated System$1,463
Avenir$174
ROSA-Knee$155
Tandem$138
Journey II XR$117
Navio Surgical System$117

How this compares

$986,213 in reported general payments places this provider in the 90th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.

See all adult reconstructive orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024

$325,469

Medicare patients

473

Services billed

3,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone Hcl	30	$228

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in New York

Seth JerabekNew York$7.1M
Jose RodriguezNew York$3.4M
Friedrich BoettnerNew York$2.9M
Jonathan VigdorchikNew York$2.3M
William LongNew York$1.5M
Peter SculcoNew York$1.5M
Roshan ShahNew York$1.3M
Herbert CooperNew York$1.3M
Patrick MeereNew York$191K
Eytan DebbiNew York$168K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →